Table 2.
Comparative analysis of patient characteristics and menopausal status according body mass index (kg/m2 ) status of studied patients
| BMI<25 kg/m2 | 25.0≤BMI< 30.0 kg/m2 | BMI≥30 kg/m2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre menopausal | Post menopausal | P value | Pre menopausal | Post menopausal | P value | Pre menopausal | Post menopausal | P-value | |
| Mean age (SD) | 47.57 (8.27) | 66.12 (9.36) | 49.31 (7.86) | 65.29 (8.855) | 50.62 (7.56) | 64.67 (8.28) | |||
| Surgery Type | |||||||||
| Quadrantectomy (BCS) | 664 (57.7%) | 436 (49.1%) | <0.001 | 991 (61.4%) | 849 (58.2%) | <0.001* | 585 (61.4%) | 718 (62.7%) | 0.06 |
| Mastectomy | 417 (36.1%) | 417 (46.9%) | 508 (31.4%) | 553 (37.9%) | 304 (31.9%) | 374 (32.6%) | |||
| Quadrantectomy (BCS) ,then Mastectomy | 69 (6.0%) | 28 (3.1%) | 111 (6.9%) | 49 (3.4%) | 111 (6.9%) | 49 (3.4%) | |||
| Stage | |||||||||
| 1 | 242 (33.5%) | 158 (31.7%) | 0.16 | 313 (29.4%) | 267 (30.8%) | 0.17 | 192 (29.4%) | 184 (26.9%) | 0.51 |
| 2 | 427 (59.1%) | 288 (57.8%) | 655 (61.6%) | 503 (58.1%) | 392 (60.1%) | 420 (61.4%) | |||
| 3 | 53 (7.3%) | 52 (10.4%) | 95 (8.9%) | 96 (11.1%) | 68 (10.4%) | 80 (11.7%) | |||
| Permanent Pathology Multifocal | |||||||||
| No | 1049 (91.2%) | 833 (94.6%) | 0.004 | 1479 (91.9%) | 1387 (95.7%) | <0.001 | 867 (91.4%) | 1070 (94.1%) | 0.01 |
| Yes | 101 (8.8%) | 48 (5.4%) | 867 (8.1%) | 1070 (4.3%) | 82 (8.6%) | 67 (5.9%) | |||
| Permanent Pathology Tumor Grade | |||||||||
| 1 | 174 (16.7%) | 184 (23.1%) | <0.001 | 232 (15.7%) | 255 (19.5%) | 0.01 | 149 (17.3%) | 185 (17.8%) | 0.01 |
| 2 | 638 (61.3%) | 480 (60.2%) | 921 (62.5%) | 806 (61.7%) | 491 (57.0%) | 645 (62.2%) | |||
| 3 | 228 (21.9%) | 134 (16.8%) | 321 (21.8%) | 246 (18.8%) | 222 (25.8%) | 207 (20.0%) | |||
| Invasion | |||||||||
| Non | 587 (51.0 %) | 414 (47.0 %) | 0.06 | 756 (47%) | 626 (43.2) | 0.03 | 439 (46.3%) | 499 (43.9%) | 0.3 |
| Vascular | 271 (23.6 %) | 217 (24.6 %) | 392 (24.3%) | 406 (28.0%) | 239 (25.2%) | 315 (27.7%) | |||
| Preneural | 75 (6.5 %) | 76 (8.6 %) | 120 (7.5%) | 110 (7.6%) | 68 (7.2%) | 80 (7.0%) | |||
| Both of them | 178 (15.5 %) | 155 (17.6 %) | 290 (18.0%) | 278 (19.2%) | 170 (17.9%) | 217 (19.1%) | |||
| Lymphatic , Vascular | 39 (3.4 %) | 19 (2.2 %) | 52 (3.2%) | 30 (2.1%) | 33 (3.5%) | 26 (2.3%) | |||
| Axillary Type | |||||||||
| ALND at first | 488 (42.7%) | 403 (47.5%) | 0.07 | 660 (41.3%) | 678 (47.8%) | 0.002 | 381 (40.5%) | 442 (39.9%) | 0.56 |
| SLNB | 458 (40.1%) | 323 (38.0%) | 682 (42.7%) | 543 (38.3%) | 151 (16.0%) | 162 (14.6%) | |||
| SLNB then ALND | 197 (17.2%) | 123 (14.5%) | 255 (16.0%) | 198 (14.0%) | 409 (43.5%) | 503 (45.4%) | |||
| Hormone receptor | |||||||||
| Luminal A | 564 (49.0%) | 406 (46.1%) | <0.001 | 772 (48.0%) | 717 (49.4%) | <0.001 | 449 (47.3%) | 579 (50.9%) | 0.007 |
| Luminal B | 211 (18.3%) | 129 (14.6%) | 288 (17.9%) | 187 (12.9%) | 142 (15.0%) | 149 (13.1%) | |||
| Her2 | 80 (7.0%) | 71 (8.1%) | 143 (8.9%) | 135 (9.3%) | 102 (10.7%) | 81 (7.1%) | |||
| Triple Negative | 130 (11.3%) | 88 (10.0%) | 172 (10.7%) | 110 (7.6%) | 106 (11.2%) | 113 (9.9%) | |||
| Preoperative Chemotherapy | |||||||||
| No | 892 (77.6%) | 753 (85.5%) | <0.001 | 1300 (80.7%) | 1248 (86.1%) | <0.001 | 776 (81.8%) | 976 (85.8%) | 0.01 |
| Yes | 258 (22.4%) | 128 (14.5%) | 310 (19.3%) | 202 (13.9%) | 173 (18.2%) | 161 (14.2%) | |||
| Postoperative Chemotherapy | |||||||||
| No | 154 (13.4%) | 152 (17.3%) | 0.01 | 185 (11.5%) | 228 (15.7%) | <0.001 | 106 (11.2%) | 164 (14.4%) | 0.01 |
| Yes | 996 (86.6%) | 729 (82.7%) | 1425 (88.5%) | 1222 (84.3%) | 843 (88.8%) | 973 (85.6%) | |||
| Radiotherapy postoperative | |||||||||
| No | 324 (36.8%) | 204 (17.7%) | <0.001 | 410 (28.3%) | 280 (17.4%) | <0.001 | 272 (23.9%) | 162 (17.1%) | <0.001 |
| Yes | 557 (63.2%) | 946 (82.3%) | 1040 (71.7%0 | 1330 (82.6%) | 865 (76.1%) | 787 (82.9%) | |||
| Hormone therapy | |||||||||
| No | 278 (24.2%) | 211(24.0%) | 0.9 | 392 (24.3%) | 328 (22.6%) | 0.26 | 268 (28.2%) | 261 (23.0%) | 0.006 |
| Yes | 872 (75.8%) | 670 (76.0%) | 1218 (75.7%) | 1122 (77.4%) | 681 (71.8%) | 876 (77.0%) | |||